What is Zacks Research’s Estimate for Cencora Q2 Earnings?

Cencora, Inc. (NYSE:COR) – Zacks Research lifted their Q2 2026 earnings estimates for Cencora in a research note issued to investors on Wednesday, May 28th. Zacks Research analyst I. Bandyopadhyay now anticipates that the company will post earnings of $4.78 per share for the quarter, up from their prior estimate of $4.45. The consensus estimate for Cencora’s current full-year earnings is $15.37 per share. Zacks Research also issued estimates for Cencora’s Q1 2027 earnings at $4.17 EPS and Q2 2027 earnings at $5.26 EPS.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating analysts’ consensus estimates of $4.07 by $0.35. The business had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The company’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.80 earnings per share.

A number of other equities analysts have also weighed in on COR. Wells Fargo & Company raised shares of Cencora from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $274.00 to $337.00 in a research report on Tuesday. Robert W. Baird upped their price target on shares of Cencora from $314.00 to $350.00 and gave the stock an “outperform” rating in a research report on Thursday, May 8th. Evercore ISI upped their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Morgan Stanley set a $288.00 price target on shares of Cencora in a research report on Tuesday, April 15th. Finally, Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $306.91.

Cencora Stock Performance

NYSE:COR opened at $291.58 on Monday. The firm has a 50 day simple moving average of $285.59 and a 200-day simple moving average of $259.30. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The firm has a market cap of $56.52 billion, a PE ratio of 41.48, a P/E/G ratio of 1.31 and a beta of 0.60. Cencora has a 1-year low of $218.65 and a 1-year high of $309.35.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 annualized dividend and a dividend yield of 0.75%. Cencora’s dividend payout ratio (DPR) is presently 25.52%.

Insider Activity

In other Cencora news, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction on Monday, March 24th. The shares were sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the transaction, the executive vice president now directly owns 14,665 shares in the company, valued at $3,934,326.20. This represents a 21.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Lazarus Krikorian sold 2,000 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at approximately $5,241,249.24. The trade was a 9.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 40,253 shares of company stock worth $11,102,417. 10.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Net Worth Advisory Group lifted its position in shares of Cencora by 1.4% in the 1st quarter. Net Worth Advisory Group now owns 2,645 shares of the company’s stock worth $736,000 after buying an additional 36 shares during the last quarter. Obermeyer Wealth Partners increased its holdings in shares of Cencora by 1.3% in the 1st quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company’s stock worth $758,000 after acquiring an additional 36 shares during the period. Cromwell Holdings LLC increased its holdings in shares of Cencora by 9.5% in the 1st quarter. Cromwell Holdings LLC now owns 450 shares of the company’s stock worth $125,000 after acquiring an additional 39 shares during the period. Pinnacle Wealth Management Advisory Group LLC increased its holdings in shares of Cencora by 2.7% in the 1st quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,565 shares of the company’s stock worth $435,000 after acquiring an additional 41 shares during the period. Finally, Whittier Trust Co. increased its holdings in shares of Cencora by 0.6% in the 4th quarter. Whittier Trust Co. now owns 7,856 shares of the company’s stock worth $1,765,000 after acquiring an additional 44 shares during the period. 97.52% of the stock is currently owned by institutional investors.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.